Your browser doesn't support javascript.
loading
HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection.
VanderVeen, Laurie A; Selzer, Lisa; Moldt, Brian; Parvangada, Aiyappa; Li, Jiani; Ananworanich, Jintanat; Crowell, Trevor A; Eron, Joseph J; Daar, Eric S; Haubrich, Richard; Geleziunas, Romas; Cyktor, Joshua; Mellors, John W; Callebaut, Christian.
Affiliation
  • VanderVeen LA; Gilead Sciences, Inc., Foster City, CA, USA.
  • Selzer L; Gilead Sciences, Inc., Foster City, CA, USA.
  • Moldt B; Gilead Sciences, Inc., Foster City, CA, USA.
  • Parvangada A; GSK Vaccines, Rixensart, Belgium (Current).
  • Li J; Gilead Sciences, Inc., Foster City, CA, USA.
  • Ananworanich J; Gilead Sciences, Inc., Foster City, CA, USA.
  • Crowell TA; Amsterdam University Medical Centers, and Department of Global Health, Amsterdam Institute for Global Health & Development, Amsterdam, Netherlands.
  • Eron JJ; U.S. Military HIV Research Program at Walter Reed Army Institute of Research, Silver Spring, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD.
  • Daar ES; University of North Carolina at Chapel Hill, NC.
  • Haubrich R; The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA.
  • Geleziunas R; Gilead Sciences, Inc., Foster City, CA, USA.
  • Cyktor J; Gilead Sciences, Inc., Foster City, CA, USA.
  • Mellors JW; University of Pittsburgh, Pennsylvania, PA, USA.
  • Callebaut C; University of Pittsburgh, Pennsylvania, PA, USA.
AIDS ; 38(4): 607-610, 2024 03 15.
Article de En | MEDLINE | ID: mdl-38416554
ABSTRACT
We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood mononuclear cells from 89 people with HIV who initiated antiretroviral therapy (ART) during acute and early HIV-1 infection (AEHI). HIV-1 diversity and predicted bNAb susceptibility were comparable across AEHI. Diversity evolution was not observed during ART, suggesting (pro)viruses at initiation or during treatment may identify individuals with susceptible virus for bNAb interventional trials.
Sujet(s)
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Infections à VIH / VIH-1 (Virus de l'Immunodéficience Humaine de type 1) / Séropositivité VIH Limites: Humans Langue: En Journal: AIDS Sujet du journal: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Infections à VIH / VIH-1 (Virus de l'Immunodéficience Humaine de type 1) / Séropositivité VIH Limites: Humans Langue: En Journal: AIDS Sujet du journal: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni